Samsung Biologics proposes $1.8B acquisition of PolyPeptide to enter fast-growing obesity peptide market

Samsung Biologics, a South Korean contract development and manufacturing organization, announced an offer to acquire Swiss CDMO PolyPeptide for CHF 1.46 billion (about $1.8 billion).

PolyPeptide specializes in peptide production, including GLP‑1 medicines used for obesity and diabetes, and reported 15.6 % revenue growth last year. The company expects sales to rise 20‑25 % this year and sees expanding profit margins.

The deal would give Samsung Biologics a foothold in the rapidly expanding peptide market that has been driven by the success of drugs such as tirzepatide and semaglutide. Samsung has traditionally focused on antibody‑based therapeutics.

PolyPeptide operates six GMP‑certified development and manufacturing sites across Europe, the United States and India and employs more than 1,400 staff, providing Samsung with a global peptide manufacturing platform.